The content on this site is intended for healthcare professionals only
Dr Takayuki Yoshino presents his study into trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer.
He discusses the methodology for his data analysis study where the team searched multiple databases; only randomised controlled trials (RCTs), non-RCTs, and prospective observational studies of previously treated patients with mCRC were evaluated.
Dr Yoshino summarises the outcome of the meta-analysis study which suggested that FTD/TPI + BEV provides benefits over FTD/TPI in patients with refractory mCRC and has a similar safety profile, but it is associated with a higher rate of grade ≥3 neutropenia.
Watch our interview with Dr Yoshino here
Watch Dr Eng comment on the study here
Watch Dr Cremolini comment on the study here
Read the news story on the study here
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
OncoAlert Round Up for August 4th - 10th, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1
